Tomatoes, Lycopene, and Prostate Cancer: What Have We Learned from Experimental Models?

Area of Science:

• Oncology
• Nutritional Science
• Preclinical Research

Background:

• Human studies suggest tomatoes and lycopene may reduce prostate cancer risk.
• Epidemiological data alone cannot establish causality.
• Preclinical models offer controlled environments to study diet-cancer relationships.

Purpose of the Study:

• To review existing preclinical studies on tomatoes and lycopene in prostate cancer models.
• To assess the anti-cancer effects of tomatoes and lycopene in various animal models.
• To identify knowledge gaps in understanding their mechanisms and effective application.

Main Methods:

• Review of published studies using preclinical models of prostate carcinogenesis and tumorigenesis.
• Analysis of data from transplantable xenograft, chemically-induced, and genetically-driven carcinogenesis models.
• Inclusion of studies using the transgenic adenocarcinoma of the mouse prostate (TRAMP) model.

Main Results:

• Tomatoes and their components demonstrate anti-prostate cancer activity in preclinical models.
• Lycopene shows anticancer effects, though outcomes vary by model, dose, and duration.
• Early and sustained interventions appear more effective.

Conclusions:

• Tomatoes and lycopene exhibit anti-prostate cancer effects in rodent models.
• Lycopene is likely one of several bioactive compounds in tomatoes with anticancer properties.
• Further research on dose-response and molecular mechanisms is crucial for human trials.